Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.40%
SPX
+0.36%
IXIC
+0.99%
FTSE
+0.32%
N225
-0.88%
AXJO
-1.82%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...
Join our newsletter to keep up to date with us!

Key Stats

Market Cap
277.58M
Dividend Yield
0.00%
P/E Ratio
-4.15
EPS
-0.33
Revenue
198.77M
Avg. Volume
424.70K

About

What does VNDA do?
Vanda Pharmaceuticals, headquartered in Washington, D.C., develops therapies for unmet medical needs and has three commercial products, including HETLIOZ and Fanapt. The company also has multiple drugs in development.
Sector
💻 Health Care
IPO
CEO
Employees
368
Headquarters
District Of Columbia, USA
Website
http://www.vandapharma.com

Recently from Cashu

publisher logo
Cashu

Vanda Pharmaceuticals Secures Orphan Drug Designation for VGT-1849B in Polycythemia Vera Treatment

3 days ago
publisher logo
Cashu

Vanda Pharmaceuticals Secures FDA Orphan Drug Designation for Polycythemia Vera Treatment VGT-1849B

5 days ago
publisher logo
Cashu

Vanda Pharmaceuticals Challenges FDA's Generic Drug Approvals for Hetlioz®

10 days ago
Stocks
Health Care
vnda
Vanda Pharmaceuticals
NASDAQ: VNDA
+0.07 (+1.49%)
4.78
USD
At close at Sep 03, 14:09 UTC
Summary
News
Signals
Benchmarks
Financials